carboxymethylidene-triphenylphosphorane | 15677-02-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: carboxymethylidene-triphenylphosphorane
• 英文别名: (triphenylphosphoranylidene)acetic acid；(carboxymethylene)triphenylphosphorane；Carboxymethylene-triphenylphosphorane；carboxymethylenetriphenylphosphorane；(carboxymethylene)-triphenylphosphorane；(carboxymethylene)triphenyl phosphorane；Carboxymethylene triphenylphosphorane；2-(triphenyl-λ5-phosphanylidene)acetic acid
• CAS: 15677-02-8
• 化学式: C₂₀H₁₇O₂P
• 分子量: 320.328
• InChiKey: PHGLYQGVAGLHTN-UHFFFAOYSA-N

物化性质

• 熔点：
  121-122 °C
• 沸点：
  516.6±33.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-氯-3-苯并呋喃酮 、 carboxymethylidene-triphenylphosphorane 以 甲苯 为溶剂， 反应 48.0h， 以75%的产率得到ethyl (5-chloro-1-benzofuran-3-yl)acetate
  参考文献：
  名称：

  Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use

  摘要：

  3-哌啶基-1H-吲哚和3-(1,2,3,6-四氢吡啶-4-基)-1H-吲哚衍生物已被披露。还披露了使用这些衍生物以及含有这些衍生物的组合物在预防和/或治疗血清素紊乱，如抑郁症和焦虑症方面的方法。此外，还披露了制备3-哌啶基-1H-吲哚和3-(1,2,3,6-四氢吡啶-4-基)-1H-吲哚衍生物的方法。

  公开号：

  US20050004162A1

文献信息

• NEW STRIGOLACTONE ANALOGUES AND THE USE THEREOF FOR THE TREATMENT OF PLANTS
  申请人：INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE

  公开号：US20150141255A1

  公开（公告）日：2015-05-21

  A compound of general formula (I): in which X represents O, S, NH or an N-alkyl radical, R 1 and R 2 , identical or different, each represent H or a C 1 -C 10 hydrocarbon radical, R 1 and R 2 not both representing H, R 3 represents a C 1 -C 10 hydrocarbon radical, and R represents a phenyl radical monosubstituted or disubstituted by a substituent Y and, if applicable, a substituent Z, chosen from Cl, Br, I and CF 3 , or R represents a C═R 4 (R 5 ) radical in which R 4 represents an hydrocarbon radical and R 5 represents a linear or branched, saturated or unsaturated, hydrocarbon radical, optionally substituted, a COR 6 group or a CO 2 R 6 group, where R 6 represents a hydrogen atom or a linear or branched, saturated or unsaturated, hydrocarbon radical. This compound can be used for the treatment of higher plants for controlling their growth and architecture.

  通式（I）的化合物： 其中X代表O、S、NH或N-烷基基团，R1和R2，相同或不同，各自代表H或C1-C10烃基，R1和R2不同时代表H，R3代表C1-C10烃基，R代表被取代基团Y和如适用的取代基团Z选择自Cl、Br、I和CF3的苯基单取代或双取代基团，或R代表C═R4（R5）基团，其中R4代表烃基团，R5代表线性或支链、饱和或不饱和、可选择取代的烃基团、COR6基团或CO2R6基团，其中R6代表氢原子或线性或支链、饱和或不饱和的烃基团。该化合物可用于治疗高等植物，控制其生长和结构。
• IDO INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160289171A1

  公开（公告）日：2016-10-06

  There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

  已披露的化合物可调节或抑制吲哌酮胺2,3-二氧化酶（IDO）的酶活性，含有该化合物的药物组合物以及利用本发明的化合物治疗增殖性疾病，如癌症、病毒感染和/或炎症性疾病的方法。
• Certain pyrazoline derivatives with kinase inhibitory activity
  申请人：Adams Ruth S.

  公开号：US20080171754A1

  公开（公告）日：2008-07-17

  The present invention provides certain pyrazoline compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions and methods of using the compositions in the treatment of various diseases.

  本发明提供了某些吡唑啉化合物，可用作蛋白激酶的抑制剂。该发明还提供了药物组合物和使用这些组合物治疗各种疾病的方法。
• [EN] PYRROLOPYRIMIDINES<br/>[FR] PYRROLOPYRIMIDINES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009016132A1

  公开（公告）日：2009-02-05

  The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are polo-like kinase (PLKs) inhibitors useful for the treatment of disease states mediated by PLK, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumour growth, rheumatoid arthritis, restenosis and atherosclerosis.

  本发明涉及化合物或其药用盐，制备它们的方法，含有它们的药物组合物以及它们在治疗中的用途。该发明特别涉及一类极化样激酶（PLKs）抑制剂化合物，用于治疗由PLK介导的疾病状态，特别是PLK4，特别是在治疗涉及异常细胞增殖的病理过程中有用的化合物，如肿瘤生长、类风湿性关节炎、再狭窄和动脉粥样硬化。
• [EN] HISTONE DEMETHYLASE INHIBITORS<br/>[FR] INHIBITEURS D'HISTONES DÉMÉTHYLASES
  申请人：CHRYSALIS INC

  公开号：WO2017143011A1

  公开（公告）日：2017-08-24

  This disclosure relates to compounds that inhibit histone demethylase activity. In particular, the disclosure relates to compounds that inhibit histone lysine demethylase KDM5B, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions disclosed herein.

  这份披露涉及抑制组蛋白去甲基化酶活性的化合物。具体而言，该披露涉及抑制组蛋白赖氨酸去甲基化酶KDM5B的化合物，以及使用这些化合物和药物组合物的方法，例如使用本文披露的化合物和药物组合物治疗癌症的方法。